This content is machine translated HER2+ early breast cancer DESTINY-Breast11 – neoadjuvant T-DXd without anthracyclines The phase III DESTINY-Breast11 trial shows that neoadjuvant trastuzumab deruxtecan (T-DXd) could provide an anthracycline-free treatment option for HER2-positive early breast cancer. The results suggest an effective and better tolerated...…
View Post 2 min This content is machine translated Pancreatic Cancer Resection outcome and pCR rate improved Chemotherapy (CT) is the standard treatment for non-resectable, locally advanced pancreatic cancer. The CONKO-007 study investigated the role of sequential CT and chemoradiotherapy (CRT). The first results have now been…
